RegenoCell Therapeutics, Inc.(fka RCLL)

[hawkeye612]

ANNUAL REPORT OUT: It looks pretty much as expected, revenues $910,000 for the year. Assets in the 350k range, allot of debt over 4 million dollars. Common shares still under 82 million so no dillution. The good news, STEM is trading at 0.74 cents per share with only a little over 2 million dollars in annual revenue, and a balance sheet that does not look any better then RCLL. So why shouldn't this one be trading at least at in the .25 cent range?

One other thought patient cost for treatment is $55,000 and their break even I believe is around 6 patients per month? So really a very small amount of patients to break even. It is expected that they will pay for their operating expenses and be current on their debt with the patients that they are treating now per month. Very Positive! Also taking steps to increase exposure.. through greater distribution efforts.

Bottem line is this is one of the company that is on the cusp of new generation of treatments. Should be trading much higher then less then a penny!!